MISUSE OF DRUGS (DESIGNATION) ORDER 2017
S.I. No. 174 of 2017

MISUSE OF DRUGS (DESIGNATION) ORDER 2017

I, CATHERINE BYRNE, Minister of State at the Department of Health, in exercise of the powers conferred on me by section 13 of the Misuse of Drugs Act 1977 (No. 12 of 1977) and the Health (Delegation of Ministerial Functions) (No. 3) Order 2016 (S.I. No. 511 of 2016), hereby order as follows:

1. This Order may be cited as the Misuse of Drugs (Designation) Order 2017.

2. This Order comes into operation on 4 May 2017.


4. The drugs specified in Schedule 1 are designated as drugs to which subsection (1) of section 13 of the Principal Act applies.

5. The manufacture, production, preparation, sale, supply, distribution and possession of the drugs specified in Schedule 1 is unlawful except for the purposes specified in Schedule 2.

6. It is unlawful for any person who is either a practitioner or a pharmacist to have in his possession the drugs specified in Schedule 1, or to do in relation to any such drugs any of the things mentioned in subsection (2) of section 5 (as amended by section 3 of the Misuse of Drugs (Amendment) Act 2016 (No. 9 of 2016)) of the Principal Act except under a licence or other authority issued by the Minister.

Notice of the making of this Statutory Instrument was published in “Iris Oifigiúil” of 5th May, 2017.
SCHEDULE 1

1. The following substances and products, namely:

   (a) \( N \)-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
   (otherwise known as Clockwork Orange, 5F AKB48)

   5-(2-Aminopropyl)indole (otherwise known as 5-IT)

   1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone

   \( N \)-(1-Benzyl-4-piperidyl)propionanilide

   2-(4-Bromo-2,5-dimethoxyphenyl)-\( N \)-[(2-methoxyphenyl)methyl]ethanamine
   (otherwise known as 25B-NBOMe)

   1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (otherwise known as
   BromodragonFLY)

   Bufotenine

   Cannabinol, except where contained in Cannabis or cannabis resin

   Cannabinol derivatives

   Cannabis (not being a preparation specified in paragraph 5 of Part 1 of
   Schedule 4 of the Misuse of Drugs Regulations 2017 (S.I. No. 173 of
   2017))

   Cannabis resin

   Cathinone

   2-(4-Chloro-2,5-dimethoxyphenyl)-\( N \)-[(2-methoxyphenyl)methyl]ethanamine
   (otherwise known as 25C-NBOMe)

   1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (otherwise known as MT-
   45)

   Coca leaf

   Concentrate of poppy straw

   3,4-Dichloro-\( N \)-[[1-(dimethylamino)cyclohexyl]methyl]benzamide
   (otherwise known as AH-7921)

   [2,3–Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
   benzoazin-6-yl]-1-naphthalenylmethanone

   \( N,N \)-Diethyltryptamine

   2,5-Dimethoxy-x,4-dimethylphenethylamine
\(N,N\)-Dimethyltryptamine

3-Dimethylheptyl-11-hydroxyhexahydrocannabinol

Eticyclidine

Etryptamine

1-(2-Fluorophenyl)-2-methylaminopropan-1-one

1-(3-Fluorophenyl)-2-methylaminopropan-1-one

1-(4-Fluorophenyl)-2-methylaminopropan-1-one

9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate

\(N\)-Hydroxy-tenamphetamine

2-(4-Iodo-2,5-dimethoxyphenyl)-\(N\)-[(2-methoxyphenyl)methyl]ethanamine (otherwise known as 25I-NBOMe)

Khat (being the leaves of \textit{Catha edulis} (Celastraceae))

Lysergamide

Lysergide and other \(N\)-alkyl derivatives of lysergamide

Mescaline

Methcathinone

2-(3-Methoxyphenyl)-2-(ethylamino)cyclohexanone (otherwise known as methoxetamine)

1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one

Methyl \((2S,4aR,6aR,7R,10aS,10bR)-9\text{-acetyloxy}-2-(furan-3-yl)-6a,10b\text{-dimethyl}-4,10\text{-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1\text{-H-}}\text{benzo[f]isochromene-7-carboxylate (otherwise known as Salvinorin A)}\)

and any product, whether natural or otherwise, including any plant or plant material of any kind or description, which contains any proportion of the said substance

2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one

2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one

4-Methyl-aminorex
Methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (otherwise known as MDMB CHMICA)

Methyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3a]quinolizin-2-yl]-3-methoxyprop-2-enoate (otherwise known as 7-Hydroxymitragynine) and any product, whether natural or otherwise, including any plant or plant material of any kind or description, which contains any proportion of the said substance

Methyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3a]quinolizin-2-yl]-3-methoxyprop-2-enoate (otherwise known as Mitragynine) and any product, whether natural or otherwise, including any plant or plant material of any kind or description, which contains any proportion of the said substance

4-Methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine (otherwise known as 4,4'-DMAR)

α-Methyl-4-(methylthio)phenethylamine

1-(4-Methylphenyl)-2-methylaminopropan-1-one

Psilocin

Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (otherwise known as Clockwork Orange, PB22)

Raw opium

Rolicyclidine

Tenocyclidine

N-[1-(2-Thenyl)-4-piperidyl]propionanilide

(b) Any substance (not being bupropion, diethylpropion or pyrovalerone) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways:

(i) by substitution in the phenyl ring to any extent with alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylenedioxy, haloalkyl or halo substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;

(ii) by substitution at the 2- or 3-position of the propanone side-chain with an alkyl substituent;

(iii) by substitution at the nitrogen atom with one or more alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

(c) Any substance structurally derived from 2-amino-1-propanone by substitution at the 1-position with any monocyclic, or fused-polycyclic ring
system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the substance is further modified in any of the following ways:

(i) by substitution in the ring system to any extent with alkyl, alkenyl, alkylnyl, alkoxy, alkylthio, haloalkyl or halo substituents, whether or not further substituted in the ring system by one or more other univalent substituents;

(ii) by substitution at the 3-position with an alkyl substituent;

(iii) by substitution at the 2-amino nitrogen atom with one or more alkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.

(d) Any substance structurally derived from 3-(1-benzoyl)indole or 3-(1-naphthoyl)indole by modification in any of the following ways:

(i) by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl;

(ii) by replacement of one or more hydrogen atoms of any of the substituents referred to in clause (i), with a halo substituent;

whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl or naphthyl ring to any extent.

(e) 1-Benzylpiperazine or any substance (not being a substance specified in Schedule 3 of the Misuse of Drugs Regulations 2017) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways:

(i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;

(ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halo or haloalkyl groups.

(f) Any substance (not being a substance specified in Schedule 2 of the Misuse of Drugs Regulations 2017) structurally derived from fentanyl by modification in one or more of the following ways, that is to say:

(i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halo, haloalkyl, amino or nitro groups;

(iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halo or haloalkyl groups;

(v) by substitution at the 4-position of the piperidine ring with any alkoxy carbonyl or alkoxy alkyl or acyloxy group;

(vi) by replacement of the N-propionyl group by another acyl group.

(g) Any substance structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.

(h) Any substance structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(i) Any substance structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(j) Any substance structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

(k) Any substance (not being a substance specified in Schedule 2 of the Misuse of Drugs Regulations 2017) structurally derived from pethidine by modification in one or more of the following ways, that is to say:

(i) by replacement of the 1-methyl group by an acyl, alkyl (whether or not unsaturated), benzyl or phenethyl group, whether or not further substituted;

(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halo or haloalkyl groups;

(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy carbonyl or any alkoxy alkyl or acyloxy group;

(v) by formation of an N-oxide or of a quaternary base.
(l) Any substance (not being methoxyphenamine) structurally derived from phenethylamine, an \(N\)-alkyl-phenethylamine, \(x\)-methylphenethylamine, an \(N\)-alkyl-\(x\)-methylphenethylamine, \(x\)-ethylphenethylamine, or an \(N\)-alkyl-\(x\)-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halo substituents, whether or not further substituted in the ring by one or more other univalent substituents.

(m) Any substance structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.

(n) Any fungus containing any proportion of Psilocin or of an ester of Psilocin.

(o) 1,2,3,4-Tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-2-amine or 2,3-dihydro-\(1H\)-inden-2-amine or any substance structurally derived from 1,2,3,4-tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-2-amine or 2,3-dihydro-\(1H\)-inden-2-amine by modification in any of the following ways:

(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkenyl, alkynyl, alkylthio, alkylenedioxy, haloalkyl, hydroxy or halo substituents, whether or not further substituted by one or more other univalent substituents;

(ii) by mono- or di-substitution at the nitrogen atom with alkyl, alkenyl, alkynyl or haloalkyl groups or by inclusion of the nitrogen atom in a cyclic structure.

(p) Any substance structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the side-chain with one or more alkyl substituents but no other substituent.

2. Any stereoisomeric form of a substance specified in paragraph 1.

3. Any ester or ether of a substance specified in paragraph 1 or 2.

4. Any salt of a substance specified in any of paragraphs 1, 2 or 3.

5. Any preparation or other product containing any proportion of a substance or product specified in any of paragraphs 1, 2, 3 or 4, not being a preparation specified in Schedule 5 of the Misuse of Drugs Regulations 2017.
SCHEDULE 2

The following purposes, namely:—

(a) research, forensic analysis or use as an essential intermediate or starting material in an industrial manufacturing process;

(b) the growing of hemp from seed varieties specified, by the Commission of the European Communities, as being eligible for the purposes of Article 1 of Regulation (EU) No. 1307/2013 of the European Parliament and of the Council of 17 December 20131; subject to such licensing provisions under the Principal Act and the Regulations made thereunder as are applicable.

GIVEN under my Hand,
2 May 2017.

CATHERINE BYRNE,
Minister of State at the Department of Health.

---

EXPLAINATORY NOTE

(This note is not part of the Instrument and does not purport to be a legal interpretation.)

Sections 4 (2) and 5 (2) of the Misuse of Drugs Act 1977 as amended, require provision to be made in Regulations to allow the use for medical purposes of the drugs specified in the Schedule to the Act.

That obligation is removed, however, in the case of any such drug which is designated by order under section 13 of the Act as a drug to which that section is to apply. This Order designates for that purpose the drugs specified in the Schedule to the Order since it would not be in the public interest that they should be so available.